ChargePoint partners with Farmat on HPAPI powder transfer

Published: 22-May-2023

The companies have created an integrated valve solution capable of allowing operators to take a product sample during the course of the production process

Powder transfer specialist ChargePoint Technology has joined forces with sampling device specialist Famat Sampling, to tackle one of the industry’s most challenging containment problems. 

The pharmaceutical suppliers have created an integrated valve solution capable of allowing operators to take a product sample during the course of the production process for quality analysis while maintaining optimum containment and sterile integrity. 

The powerful combination of ChargePoint Technology’s split butterfly valve and Famat Sampling’s 125-TC/OEL valve creates a secure and sterile environment for high- potency and sterile powder samples to be taken. 

The interconnected system forms an airtight seal that prevents a dead zone and allows samples of highly potent, toxic or sterile powders to be transferred into containers safely and securely, maintaining OEB4 and OEB5 level compliance. 

The integrated network of valves allow for rigorous testing capabilities and ensure that product quality is maintained during the process and it is FDA compliant. The combination of products help minimise risk to the operator, who could be exposed to potentially dangerous powders during the sampling process. 

Our shared depth and breadth of knowledge and experience have allowed us to create a solution

The powder product must not be altered during sampling, as oxygen or other particles could come into contact during the extraction process and damage the product. The combination of technologies from ChargePoint Technology and Famat acts as an isolator and offers users a safe method of transfer so the quality of the product can be protected. 

Christian Dunne, Head of Sterile Solutions at ChargePoint Technology, commented on the partnership: “The HPAPI market is predicted to grow by 8.7%  to reach a value of $34.97 billion by 2028, highlighting why it’s vital for drug manufacturers to invest in appropriate containment technologies, as while ensuring they are able to maintain optimum product quality. 

“During processing, manufacturers must prioritise sampling so that the quality of drug products can be assessed at various stages of the production process. Famat Sampling shares our high standards for quality. Joining forces as two recognised industry leaders in our respective fields was a no-brainer for our team. 

“Our shared depth and breadth of knowledge and experience have allowed us to create a solution that helps solve a prevalent issue for manufacturers and adds additional protection for users.” 

ChargePoint Technology offers containment and aseptic transfer valves and single-use solutions that are essential for the safe transfer of powders during pharmaceutical and biopharmaceutical manufacturing.

You may also like